The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies

Abstract

The use of BRV at doses > 5 mg/day resulted in statistically significant reduction in seizure frequency in respect to the 50% responder rate. BRV was reasonably tolerated by patients. These findings warrant confirmation in future studies.

Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis

“…Irritability was reported in 3.2% of patients receiving BRV vs. 1.1% on placebo [24]. In two pooled analyses fatigue, somnolence and dizziness were significantly associated with BRV and only in one analysis there was an association with irritability [25,26]. Even though tolerability of BRV in clinical trials was good [27], it is noteworthy that psychiatric symptoms constituted the most common type of adverse effects leading to premature treatment discontinuation in 2 larger trials [15,12].…”

Safety Profile of the Newest Antiepileptic Drugs: A Curated Literature Review

“…Efficacy and safety of BRV was analyzed in three recent meta-analysis. Tian et al [29] conducted a metaanalysis to evaluate the efficacy and safety of different doses of BRV. The data, inclusive of reports from five trials, showed that both fatigue and nasopharyngitis were significantly associated with 20 mg BRV, irritability and fatigue were associated with 50 mg BRV, and somnolence was associated with 150 mg BRV, whereas no significant differences were noted for the other common TEAEs, concluding that BRV was fairly well tolerated by patients.…”

New developments in the management of partial-onset epilepsy: role of brivaracetam

“…In the first two articles,72,73 five RCTs were reviewed, including a total of 1,639 patients; 50% responder rates and seizure-free rates were analyzed as end points for evaluating BRV efficacy. Fifty percent responder rates among patients treated with BRV 20, 50 or 100 mg/day were significantly higher than among patients receiving PBO (20 mg: relative risk [RR] =1.63, 95% CI =1.18–2.27, P =0.003; 50 mg: RR =2.00, 95% CI =1.50–2.66, P <0.00001; 100 mg: RR =1.80, 95% CI =1.12–2.88, P =0.01), while no statistically significant difference emerged from the comparison between PBO and the BRV daily dosage of 5 or 150 mg.…”